A detailed history of Prelude Capital Management, LLC transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 11,000 shares of ATHA stock, worth $7,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,000
Previous 11,000 -0.0%
Holding current value
$7,040
Previous $4,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.42 - $3.43 $2,913 - $23,790
-6,936 Reduced 38.67%
11,000 $4,000
Q2 2024

Aug 14, 2024

SELL
$1.92 - $2.71 $11,003 - $15,531
-5,731 Reduced 24.22%
17,936 $47,000
Q1 2024

May 15, 2024

SELL
$2.24 - $4.15 $17,371 - $32,183
-7,755 Reduced 24.68%
23,667 $64,000
Q4 2023

Feb 14, 2024

SELL
$1.39 - $2.46 $695 - $1,230
-500 Reduced 1.57%
31,422 $76,000
Q3 2023

Nov 14, 2023

BUY
$1.9 - $3.16 $6,080 - $10,112
3,200 Added 11.14%
31,922 $64,000
Q2 2023

Aug 14, 2023

SELL
$2.36 - $3.59 $33,594 - $51,103
-14,235 Reduced 33.14%
28,722 $84,000
Q1 2023

May 15, 2023

SELL
$2.26 - $4.22 $44,668 - $83,408
-19,765 Reduced 31.51%
42,957 $107,000
Q4 2022

Feb 14, 2023

BUY
$2.76 - $3.71 $4,140 - $5,565
1,500 Added 2.45%
62,722 $198,000
Q3 2022

Nov 14, 2022

BUY
$2.93 - $3.96 $86,206 - $116,511
29,422 Added 92.52%
61,222 $182,000
Q2 2022

Aug 15, 2022

BUY
$2.74 - $13.43 $56,992 - $279,344
20,800 Added 189.09%
31,800 $97,000
Q1 2022

May 16, 2022

BUY
$8.96 - $13.51 $98,560 - $148,610
11,000 New
11,000 $149,000
Q4 2021

Feb 14, 2022

SELL
$9.17 - $16.39 $95,368 - $170,456
-10,400 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$9.15 - $11.09 $95,160 - $115,336
10,400 New
10,400 $98,000

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $24.2M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.